Table 2.
Vaccines approved for full use or in limited use against Covid-19.
| S.No: | Vaccine name | Country | Vaccine type | Approved |
|---|---|---|---|---|
| 1 | Vaxine/CinnaGen Co.SpikoGen | Australia | Protein Subunit | Approved in 1 country |
| 2 | Zydus CadilaZyCoV-D | India | DNA | Approved in 1 country |
| 3 | Anhui Zhifei LongcomZF2001 | China | Protein Subunit | Approved in 3 countries |
| 4 | Biological E LimitedCorbevax | India | Protein Subunit | Approved in 1 country |
| 5 | CanSinoConvidecia | China | Non-replicating Viral Vector | Approved in 10 countries |
| 6 | Center for Genetic Engineering and Biotechnology (CIGB)Abdala | Cuba | Protein Subunit | Approved in 6 countries |
| 7 | Chumakov CenterKoviVac | Russia | Inactivated | Approved in 3 countries |
| 8 | FBRIAurora-CoV | Russia | Protein Subunit | Approved in 1 country |
| 9 | FBRIEpiVacCorona | Russia | Protein Subunit | Approved in 4 countries |
| 10 | GamaleyaSputnik Light | Russia | Non-replicating Viral Vector | Approved in 26 countries |
| 11 | GamaleyaSputnik V | Russia | Non-replicating Viral Vector | Approved in 74 countries |
| 12 | Health Institutes of TurkeyTurkovac | Turkey | Inactivated | Approved in 1 country |
| 13 | Instituto Finlay de Vacunas CubaSoberana 02 | Cuba | Protein Subunit | Approved in 4 countries |
| 14 | Instituto Finlay de Vacunas CubaSoberana Plus | Cuba | Protein Subunit | Approved in 1 country |
| 15 | Janssen (Johnson & Johnson)Ad26.COV2.S | USA | Non-replicating Viral Vector | Approved in 106 countries |
| 16 | Kazakhstan RIBSPQazVac | Kazakhstan | Inactivated | Approved in 2 countries |
| 17 | MedigenMVC-COV1901 | Taiwan | Protein Subunit | Approved in 2 countries |
| 18 | Minhai Biotechnology CoKCONVAC | China | Inactivated | Approved in 2 countries |
| 19 | ModernaSpikevax | USA | RNA | Approved in 85 countries |
| 20 | National Vaccine and Serum InstituteRecombinant SARS-CoV-2 Vaccine (CHO Cell) | China | Protein Subunit | Approved in 1 country |
| 21 | NovavaxNuvaxovid | USA | Protein Subunit | Approved in 36 countries |
| 22 | Organization of Defensive Innovation and ResearchFAKHRAVAC (MIVAC) | Iran | Inactivated | Approved in 1 country |
| 23 | Oxford/AstraZenecaVaxzevria | UK | Non-replicating Viral Vector | Approved in 138 countries |
| 24 | Pfizer/BioNTechComirnaty | USA/Germany | RNA | Approved in 137 countries |
| 25 | Razi Vaccine and Serum Research InstituteRazi Cov Pars | Iran | Protein Subunit | Approved in 1 country |
| 26 | Serum Institute of IndiaCovishield (Oxford/ AstraZeneca formulation) | India in Collaboration | Non-replicating Viral Vector | Approved in 47 countries |
| 27 | Serum Institute of IndiaCOVOVAX (Novavax formulation) | India | Protein Subunit | Approved in 3 countries |
| 28 | Shifa Pharmed Industrial CoCOVIran Barekat | Iran | Inactivated | Approved in 1 country |
| 29 | Sinopharm (Beijing)Covilo | China | Inactivated | Approved in 89 countries |
| 30 | Sinopharm (Wuhan)Inactivated (Vero Cells) | China | Inactivated | Approved in 2 countries |
| 31 | SinovacCoronaVac | China | Inactivated | Approved in 53 countries |
| 32 | TakedaTAK-919 (Moderna formulation) | Japan | RNA | Approved in 1 country |
| 33 | Bharat BiotechCovaxin | India | Inactivated | Approved in 13 countries |